Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLC?2 can also mediate resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Zhang, Mingzhi, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351700/
https://www.ncbi.nlm.nih.gov/pubmed/27776353
http://dx.doi.org/10.18632/oncotarget.12786
_version_ 1782514817665335296
author Wu, Jingjing
Zhang, Mingzhi
Liu, Delong
author_facet Wu, Jingjing
Zhang, Mingzhi
Liu, Delong
author_sort Wu, Jingjing
collection PubMed
description The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLC?2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibrutinib. More selective and potent BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being investigated. This review summarized the preclinical research and clinical data of ONO/GS-4059.
format Online
Article
Text
id pubmed-5351700
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53517002017-04-13 Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside Wu, Jingjing Zhang, Mingzhi Liu, Delong Oncotarget Review The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLC?2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibrutinib. More selective and potent BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being investigated. This review summarized the preclinical research and clinical data of ONO/GS-4059. Impact Journals LLC 2016-10-20 /pmc/articles/PMC5351700/ /pubmed/27776353 http://dx.doi.org/10.18632/oncotarget.12786 Text en Copyright: © 2017 Wu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Wu, Jingjing
Zhang, Mingzhi
Liu, Delong
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
title Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
title_full Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
title_fullStr Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
title_full_unstemmed Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
title_short Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
title_sort bruton tyrosine kinase inhibitor ono/gs-4059: from bench to bedside
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351700/
https://www.ncbi.nlm.nih.gov/pubmed/27776353
http://dx.doi.org/10.18632/oncotarget.12786
work_keys_str_mv AT wujingjing brutontyrosinekinaseinhibitoronogs4059frombenchtobedside
AT zhangmingzhi brutontyrosinekinaseinhibitoronogs4059frombenchtobedside
AT liudelong brutontyrosinekinaseinhibitoronogs4059frombenchtobedside

Ejemplares similares